Cellusion
Tokyo, Japan· Est.
Developing iPSC-derived corneal endothelial cell injection therapy to address the global shortage of donor corneas for transplants.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Developing iPSC-derived corneal endothelial cell injection therapy to address the global shortage of donor corneas for transplants.
Ophthalmology
Technology Platform
Differentiation of induced pluripotent stem cells (iPSCs) into mass-producible, allogeneic corneal endothelial cell substitutes (CECSi) for cell injection therapy.
Opportunities
Addressing a massive unmet need with over 10 million patients awaiting corneal transplants globally; potential for geographic expansion if the scalable, off-the-shelf product gains approval.
Risk Factors
Clinical risks inherent to novel iPSC-derived cell therapies, including safety, efficacy, and potential immunogenicity; regulatory hurdles for first-in-class products; and future competition.
Competitive Landscape
Competes against traditional donor cornea transplants and other developing cell-based therapies; key differentiation is the scalable iPSC platform and less invasive injection procedure designed for wider physician adoption.